The company has already voluntarily suspended shipments of its APls and formulations for the US market and since July 2014 has not shipped any APls or formulations to the US market except the products which are exempted from import alert, it added. "The company has responded to the USFDA inspection observations with its remediation measures and has been since working with external consultants to ensure that its remedial activities are undertaken in a proper and timely manner," Ipca Laboratories said. Shares of Ipca Laboratories were trading at Rs 642.50 in the afternoon trade on BSE, down 3.94 per cent.